51.68

1.10% 0.56

After Hours: 53.45 1.77 +3.42%

Mirum Pharmaceuticals Inc (MIRM)

Overview News Price History Option Chain Financials Why MIRM Down? Discussions Forecast

Mirum Pharmaceuticals Inc stock is traded at $51.68, with a volume of 325.46K. It is up +1.10% in the last 24 hours and up +1.55% over the past month. Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Previous Close:

$51.12

Open:

$50.97

24h Volume:

325.46K

Relative Volume:

0.80

Market Cap:

$2.56B

Revenue:

$379.25M

Net Income/Loss:

$-77.34M

P/E Ratio:

-32.06

EPS:

-1.6122

Net Cash Flow:

$-27.87M

1W Performance:

-0.94%

1M Performance:

+1.55%

6M Performance:

+5.73%

1Y Performance:

+27.45%

1-Day Range:

$50.75

$52.59

1-Week Range:

$50.75

$52.63

52-Week Range:

$36.20

$54.78

Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile

Name

Mirum Pharmaceuticals Inc

Sector

Healthcare (1161)

Industry

Biotechnology (646)

Phone

650-667-4085

Address

989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY

Employee

334

Twitter

@mirumpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

MIRM's Discussions on Twitter

Compare MIRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIRM Mirum Pharmaceuticals Inc	51.68	2.53B	379.25M	-77.34M	-27.87M	-1.6122
VRTX Vertex Pharmaceuticals Inc	456.87	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.46	59.88B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	392.24	44.31B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	670.33	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	32.46B	3.81B	-644.79M	-669.77M	-6.24

Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-19-25	Resumed	H.C. Wainwright	Buy
Apr-17-24	Initiated	Stifel	Buy
Dec-18-23	Reiterated	H.C. Wainwright	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Nov-13-23	Initiated	Morgan Stanley	Overweight
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-17-23	Resumed	Evercore ISI	Outperform
Sep-20-23	Initiated	JMP Securities	Mkt Outperform
Sep-01-22	Initiated	Citigroup	Buy
Sep-20-21	Initiated	JP Morgan	Overweight
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-25-20	Initiated	Robert W. Baird	Outperform
Aug-12-19	Initiated	Citigroup	Buy
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Guggenheim	Buy
Aug-12-19	Initiated	ROTH Capital	Buy
Aug-12-19	Initiated	Raymond James	Outperform

View All

Mirum Pharmaceuticals Inc Stock (MIRM) Latest News

Jul 31, 2025

Why Investors Shouldn't Be Surprised By Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Low P/S - 富途牛牛

Jul 31, 2025

Jul 30, 2025

Long term hold vs stop loss in Mirum Pharmaceuticals Inc.Alpha Focused Technical Trade Signals Gain Attention - metal.it

Jul 30, 2025

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - Business Wire

Jul 30, 2025

Mirum Pharmaceuticals Inc. Shows Support at Fibonacci LevelVerified Signal From Chart Patterns Detected - metal.it

Jul 30, 2025